文献速递白血病MDS 与骨髓增殖性肿瘤

PARP1作为急性髓系白血病和骨髓增生异常综合征的治疗靶点

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
PubMed 文献 · Blood Adv · 2021-01-01

本文综述PARP1在DNA损伤修复和基因表达调控中的作用,及其在骨髓增生异常综合征和急性髓系白血病病理生理与预后中的角色。文中汇总了olaparib、rucaparib、niraparib、veliparib和talazoparib等PARP1抑制剂作为单药或联合化疗、抗血管生成药物、电离辐射和免疫检查点抑制剂的研究数据,强调其在血液恶性肿瘤靶向治疗中的潜力。

要点

  • PARP1抑制剂通过合成致死效应阻碍DNA修复,可靶向治疗血液恶性肿瘤。
  • PARP1抑制剂可单用或联合化疗、抗血管生成、放疗和免疫检查点抑制剂。
  • olaparib、rucaparib、niraparib、veliparib和talazoparib的临床试验显示应用前景。

核心结论

  • PARP1在骨髓增生异常综合征和急性髓系白血病中具有重要病理生理作用,PARP1抑制剂在此类疾病中展现出有前景的临床应用价值。

研究设计与样本

  • 本文为综述,聚焦PARP1在骨髓增生异常综合征和急性髓系白血病中的生理和病理作用,并分析PARP1抑制剂的应用数据。

主要发现

  • PARP1通过结合DNA单链和双链断裂被激活,参与染色质重塑并调控基因表达。
  • PARP1抑制剂通过合成致死效应阻碍癌细胞DNA修复,最初针对乳腺癌突变细胞开发。
  • 正在进行的olaparib、rucaparib、niraparib、veliparib和talazoparib临床试验显示克服PARP1抑制剂耐药和靶向治疗血液恶性肿瘤的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Poly(ADP-ribose) polymerase 1 (PARP1) is a key mediator of various forms of DNA damage repair and plays an important role in the progression of several cancer types. The enzyme is activated by binding to DNA single-strand and double-strand breaks. Its contribution to chromatin remodeling makes PARP1 crucial for gene expression regulation. Inhibition of its activity with small molecules leads to the synthetic lethal effect by impeding DNA repair in the treatment of cancer cells. At first, PARP1 inhibitors (PARPis) were developed to target breast cancer mutated cancer cells. Currently, PARPis are being studied to be used in a broader variety of patients either as single agents or in combination with chemotherapy, antiangiogenic agents, ionizing radiation, and immune checkpoint inhibitors. Ongoing clinical trials on olaparib, rucaparib, niraparib, veliparib, and the recent talazoparib show the advantage of these agents in overcoming PARPi resistance and underline their efficacy in targeted treatment of several hematologic malignancies. In this review, focusing on the crucial role of PARP1 in physiological and pathological effects in myelodysplastic syndrome and acute myeloid leukemia, we give an outline of the enzyme's mechanisms of action and its role in the pathophysiology and prognosis of myelodysplastic syndrome/acute myeloid leukemia and we analyze the available data on the use of PARPis, highlighting their promising advances in clinical application.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kontandreopoulou CN, Diamantopoulos PT, Tiblalexi D, et al. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2021. PMID: 34529761. doi:10.1182/bloodadvances.2021004638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。